The Competition Bureau announced today that it has entered into a consent agreement with Isologic Innovative Radiopharmaceuticals Inc. (Isologic) to address competition concerns with its contracting practices in the radiopharmaceutical industry.
A Bureau investigation found that Isologic’s contractual practices with certain customers contravened the abuse of dominance provisions of the Competition Act. These practices affected certain customers purchasing radiopharmaceuticals used for single photon emission computed tomography (SPECT) scans. Affected customers were required to purchase some products exclusively from Isologic.
Isologic cooperated with the Bureau’s investigation and agreed to resolve the Bureau’s competition concerns by entering into a consent agreement.
Under the terms of the agreement, Isologic will cease using certain terms in its contracts with some customers, including legal exclusivity clauses. Isologic will also include a term in any multi-year contracts with these customers permitting them to terminate the contract prior to its expiration.
The complete consent agreement is available on the website of the Competition Tribunal.
Promoting and protecting competition and innovation in the Canadian health care sector is a key priority for the Competition Bureau. The Bureau encourages anyone who suspects an individual or a business of engaging in anti-competitive activities to file a complaint.